Coronavirus company news summary – remedesivir receives EUA from the FDA – Canadian Government to spend $175.6m on AbCellara’s antibody drugs

Allie Nawrat 4 May 2020 (Last Updated May 4th, 2020 09:56)

4 May 2020 

Gilead Sciences has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for remdesivir to treat Covid-19. The authorisation is set to allow broader access to the drug for treating hospitalised patients with severe Covid-19 across the US. Gilead will work with the government to allocate the currently limited supply of the drug. Read the full story here.

The Canadian Government has agreed to provide up to $175.6m funding to support Vancouver-based AbCellera in the identification of antibody-based therapies against Covid-19. The funds will also be used to develop technology and manufacturing infrastructure for antibody treatments for future pandemics.

Researchers at University Hospital Southampton in the UK are conducting a clinical trial to assess a new Covid-19 drug candidate developed by biotech firm Synairgen, according to the BBC. The drug candidate is made of interferon beta that is directly delivered to the airways. Initial data from the trial is set to be available by the end of next month.

Athersys and University Hospitals Cleveland Medical Center (UH Cleveland) have activated the first clinical site for the MACOVIA clinical trial of MultiStem Cell Therapy to treat acute respiratory distress syndrome (ARDS) caused by Covid-19. The primary objective of the study is the number of ventilator-free days through day 28 versus placebo.